So, when I say I expect no different outcome in humans, I mean the onset of MTD symptoms will not yet appear at highly effective levels. Moreover, there should be no expectation of any adverse or toxic reactions for at least 2 more dose increases. The 4th cohort may begin to show dose limiting symptoms, but efficacy should be well-established by the end of the 3rd round.

leads to the belief that serious price action may precede establishment of MTD?